Jan Godzinski

Jan Godzinski

Auto-generated profile, based on publicly available information

Jan Godzinski

Department of Paediatric Surgery, Marciniak Hospital, Wroclaw, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
NGNorbert Graf
Norbert Graf
CBC. Bergeron
C. Bergeron
JBJesper Sune Brok
Jesper Sune Brok
BCBeatriz de Camargo
Beatriz de Camargo
TCT. Chowdhury
T. Chowdhury
Marry van den Heuvel-EibrinkMarry van den Heuvel-Eibrink
Marry van den Heuvel-Eibrink

10 May 2022 in JCO Global Oncology
Verified
Journal Article
Open access
JAJoaquim Caetano de Aguirre-Neto
Joaquim Caetano de Aguirre-Neto
BCBeatriz de Camargo
Beatriz de Camargo
HTHarm van Tinteren
Harm van Tinteren
CBChristophe Bergeron
Christophe Bergeron
JBJesper Brok
Jesper Brok
KPKathy Pritchard-Jones
Kathy Pritchard-Jones
PURPOSE: International comparisons of patient demographics, tumor characteristics, and survival can shed light on areas for health care system improvement. The International Society of Pediatric Oncology Wilms Tumor 2001 trial/study registered patients through national clinical study groups in Western Europe and Brazil. This retrospective post hoc analysis of the International Society of Pediatric Oncology Wilms Tumor 2001 database aims to make visible and suggest reasons for any variations in outcomes. METHODS: All patients with unilateral Wilms tumor (WT), age > 6 months, treated with preoperative chemotherapy as per protocol, and registered between 2001 and 2011 were eligible. Countries were grouped to give comparable case numbers and geographical representation. Cox univariable and multivariable (MVA) statistics were applied, with the German collaborative group (Gesellschaft für Pädiatrische Onkologie und Hämatologie—Austria, Germany, and Switzerland) as reference for hazard ratios for event-free survival (EFS) and overall survival (OS). RESULTS: A total of 3,176 eligible patients were registered from 24 countries assigned into six groups. Age and histologic risk group distribution were similar across all groupings. The distribution of WT stage varied by country grouping, with 14.9% (range, 11.1%-18.2%) metastatic at diagnosis. Median follow-up was 78.9 months. For localized WT, 5-year EFS varied from 80% (Brazilian group) to 91% (French group; P < .0001), retaining significance only for Brazil in MVA ( P = .001). Five-year OS varied from 89% (Brazilian group) to 98% (French group; P < .0001). In MVA, only superior OS in France was significant ( P = .001). Five-year EFS/OS for stage IV did not vary significantly. High-risk histology and tumor volume at surgery were significantly associated with increased risk of death in MVA for metastatic disease. CONCLUSION: International benchmarking of survival rates from WT within a large trial/study database has demonstrated statistically significant differences. Clinical interpretation should take account of variation in tumor stage but also treatment factors.

23 March 2025 in Health Science Reports
Verified
Journal Article
Open access
PSPatrycja Sosnowska-Sienkiewicz
Patrycja Sosnowska-Sienkiewicz
GKGrzegorz Kowalewski
Grzegorz Kowalewski
HGHanna Garnier
Hanna Garnier
AWAnna Dominika Wojtyłko
Anna Dominika Wojtyłko
MMMaciej Murawski
Maciej Murawski
PMPrzemysław Mańkowski
Przemysław Mańkowski
Background and Aim: Pediatric surgery requires high precision and safety due to children's unique anatomy and physiology. Innovations that enhance surgical precision, reduce operative time, and improve postoperative outcomes are invaluable. Indocyanine green (ICG), a near‐infrared fluorescent dye, has received significant attention for its potential to address these needs. The study aimed to describe applications of ICH in pediatric surgery in Poland, provide evidence to support integration of ICG into pediatric surgical practice and evaluate the safety and feasibility of ICG.Methods: Data were collected from the medical records of 136 patients undergoing surgical treatment in four leading pediatric surgical clinical centers in Poland. There are four main groups of surgical procedures: oncological, gastrointestinal, urological and lymphatic. Calculations were performed using Statistica 13 by TIBCO and PQStat v. 1.8.6.120 by PQStat Software. Additionally, descriptive statistics were performed.Results: The efficacy and safety of ICG were confirmed in the entire study group. No complications were reported with the use of the indocyanine green. Exhaustive descriptive statistics presented key information on the use of ICG for each of the studied groups.Conclusions: The study validates the efficacy and safety of ICG fluorescence imaging in pediatric surgery. By enhancing surgical precision and improving postoperative outcomes, ICG represents a significant advancement in pediatric surgical care. The establishment of standardized protocols and the emphasis on specialized training will be key to maximizing the benefits of ICG.

13 March 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Rhoikos FurtwänglerRhoikos Furtwängler
Rhoikos Furtwängler
RDRana Dandis
Rana Dandis
HTHarm van Tinteren
Harm van Tinteren
NWNils Welter
Nils Welter
CVChristian Vokuhl
Christian Vokuhl
NGNorbert Graf
Norbert Graf
PURPOSE: The International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP-RTSG) classifies blastemal-type Wilms tumor (WT) after preoperative chemotherapy as high-risk (HRWT). It remains unresolved whether residual absolute volume of blastema (AVB) functions as an independent prognostic factor across WT subtypes. MATERIALS AND METHODS: AVB was calculated from preoperative tumor volume, necrosis percentage, and viable blastema using prospectively collected data from 3,459 patients with unilateral WT treated in the SIOP WT 2001 study between 2001 and 2018. Martingale residual plots defined AVB thresholds discriminating survival in localized HRWT, intermediate-/low-risk WT (IRWT/LRWT), and metastatic WT (stage IV). Complete AVB data were available for 1,802 patients (51.2%); 298 (16.5%) had stage IV disease. Of 1,504 patients with localized WT, 265 (17.6%) had HRWT, 1,203 (79.9%) had IRWT, and 36 (2.4%) had LRWT. RESULTS: Multivariable Cox regression adjusted for age, sex, and local stage confirmed significantly worse survival for patients exceeding these AVB thresholds: (1) IRWT (≥20 mL): Hazard ratio for event-free survival (EFS) 2.93 (95% CI, 2.08 to 4.12) and overall survival (OS) 2.76 (95% CI, 1.32 to 5.77); (2) HRWT (≥100 mL): EFS 2.89 (95% CI, 1.59 to 5.26) and OS 3.25 (95% CI, 1.45 to 7.27); and (3) stage IV (≥10 mL): EFS 5.78 (95% CI, 3.65 to 9.17) and OS 4.59 (95% CI, 2.57 to 8.17). Patients above these thresholds had significantly lower 2-year EFS ( P < .0001). In stage II to III IRWT patients with AVB ≥20 mL, those treated with doxorubicin had superior EFS versus those without (87.6%, 95% CI, 81.5 to 94.1 v 69.2%, 95% CI, 59.8 to 80.1; P = .0064). CONCLUSION: AVB after preoperative chemotherapy is a strong, independent predictor of both EFS and OS in WT across risk groups. An AVB of ≥20 mL identifies a clinically relevant subset of patients with IRWT who may benefit from intensified therapy with doxorubicin. These findings support the use of AVB as a stratification criterion in future SIOP-RTSG protocols.

1 January 2023
Verified
Book Chapter
Closed access
MPMateusz Paplicki
Mateusz Paplicki
JGJan Godziński
Jan Godziński
Zapewnienie bezpieczeństwa powszechnego jest jednym z podstawowych zadań współczesnego państwa. Przedmiotem działania organów administracji publicznej, a w jej ramach różnego rodzaju służb, inspekcji oraz straży, jest m.in. ochrona ludności przed zagrożeniami mogącymi naruszyć takie stany jak porządek i bezpieczeństwo publiczne, a także takie dobra chronione przez prawo jak życie, zdrowie i mienie. Wskazanie rodzajów i […]